Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
As a thought, I believe the price dropped about a dollar at the open. This would pull in a lot of daytraders, which would make up a lot of the volume. This year at ASCO a company released news of a launch of a liquid biopsy, pre market. It traded high volume in the pre-market. The stock has lesss than 14 milllion shares outstanding, but the volume that day was a staggering 27 million shares. A lot of shenanigans that day and for weeks after as they had a lot of stuck traders to clear out.
Fox,
Glad to have you back as a Long. Always appreciated your input.
So now you have 100 shares....JUST KIDDING FOX.
That may be, but the odds for approval are a lot better than they were in 2008.
Flipper,
I came across this, thought it might be of interest...
http://www.forbes.com/sites/matthewherper/2015/08/20/the-fda-is-basically-approving-everything-heres-the-data-to-prove-it/
The stock has shown weakness in the last 2 weeks. This is short interest as of 7/31. There could be substantially more shares short in the last 11 days. Look at how the shares short have grown in the last 3 months alone. Fuel for a rally.
Shorty is still selling.....
This is before the downdraft of the last 2 weeks.
http://www.nasdaq.com/symbol/tbio/short-interest
With the volume in the last few minutes .....maybe capitulation on the part of someone?
It is quite clear to me the shorts have a hold of this. I suspect they think they will get another capital raise dripping with warrants for them to cover with. The usual vulture hedge fund crap. I look at it as fuel for a rally. TBIO has repeatedly said they were looking to sell an asset to raise money if need be. Now it is a tug of war. Earnings will be out by the 15th, and I wait to hear the call.
Do not think earnings are today. Have not seen a PR that they are. Have you?
Do you think it would be better for Northwest to pay their way through a partnership, and keep more of the pie? Just the partnership alone would at least double the price, and give them credibility in the market sphere, making life a lot easier for them.
No it is not. This is also the first "Official" conference call.
Normally just a PR W/O fanfare.
I would assume FDA clearance would fix the chart....
Transgenomic has booth space at the Next Generation DX Summitt, August 18-20 2015 in Washington DC. They are also a corporate sponsor. All the big diagnostic boys are here including Life-Tech and Illumina.
http://www.nextgenerationdx.com/
http://www.nextgenerationdx.com/uploadedFiles/Next_Generation_Dx/Sponsor_and_Exhibitor/ADX-Floorplan.pdf
From Biocept PR announcing their participation:
http://finance.yahoo.com/news/biocept-announces-presentation-next-generation-110000103.html
“Liquid biopsies offer a unique opportunity to profile and monitor patients with solid tumors such as lung cancer, and we appreciate the opportunity to share our development milestones and real-world experience with the scientific community attending this prestigious industry conference,” said Dr. Arnold. “An entire day at this conference is dedicated to liquid biopsy, which is indicative of the level of interest it is generating among researchers, clinicians and the biopharma industry.”
Hattip to Soundsgood02 at YMB.
The clearance is in the hands of the FDA. You know how long they can take. We have been waiting a while, since late last year. This is what I glean from listening to the conference calls. It would seem it would be here in the short term. I think, one morning we will wake up and it will be here!
TC, there was also this today in Barrons.
Don't know if it applies here, but could have added to the panic, or a good reason for shorts to start the panic?
http://blogs.barrons.com/stockstowatchtoday/search/hedge%20biotech%20stocks/?s=hedge+biotech+stocks
I do not think Ice is affiliated with Cryoport, he is just bullish on the stock as I am. As for the other, I don't know his affiliations, but he sure does have a lot of information.
I find this post very suspicious. You know far to much, and why do you give a horses patoot what I say about Aegis. Or could it be that you are them ?
I have to agree with Ice that it is the Aegis investors, and they do not deserve to be called investors, more like thieves. They are selling the stock to get their money back and keeping the warrants.
What I mean is they did not take the 15 million, only 6 million because it was too much dilution.
What Aegis did was criminal. I think they told Cryoport management they planned on doing the offering at 6 bucks the whole time.(Just my opinion) This was trading at over 8 bucks the prior week. Then they slammed it down trying to take 50% the company. I do give Rathman and Shelton a lot of credit for telling them to take a hike.
When they reached the first interim at 66 events before the trial modification, the event produced a press release. Are we thinking no press release this time?
http://www.nwbio.com/first-interim-analysis-of-nw-bios-phase-iii-gbm-trial-triggered-by-reaching-required-number-of-events/
Where is all the selling coming from?
They are filling our tank with fuel....
http://www.nasdaq.com/symbol/tbio/short-interest
And this does not include naked shorts.
TBIO's holy grail is the liquid biopsy.
Here is a short video from Johns Hopkins that tells the potential of the liquid biopsy. We are waiting for clearance from the FDA to license this technology, while we are developing in house tests for specific cancers. If you watch the video of Mya Thomae director at Transgenomic and Illumina that Golden Gate posted, she explains the difference. In house tests do not require FDA clearance. Tbio stresses that their biopsy is 100 times more sensitive than any liquid biopsy out there.
Nice buy on Illumina...
There seems to be a lot of dots to connect from that news release, eh?
FDA clearance for Multiplexed Ice Cold PCR is coming soon. This will allow them to license this technology to everyone else's platforms, like Illumina or Life Tech. This is a liquid biopsy, which is 500 times more sensitive to anything out there. Liquid biopsies were the rage at ASCO this year. I believe this will run like a scalded cat when clearance is given, causing the current shorters to cover initiating a short squeeze.
Transgenomic Launches Most Comprehensive Genetic Test for Diagnosis of Leukodystrophy
New Test is Most Comprehensive for Definitive Diagnosis of These Devastating Genetic Disorders
Business Wire Transgenomic, Inc.
OMAHA, Neb.--(BUSINESS WIRE)--
Transgenomic, Inc. (TBIO), a global biotechnology company advancing precision medicine through advanced diagnostic tests and clinical and research services, today announced the launch of the Transgenomic Leukodystrophy NGS Panel for the diagnosis of leukodystrophy, a group of rare progressive genetic disorders that affect the central nervous system by disrupting the growth or maintenance of the myelin sheath insulating nerve cells.
Leukodystrophies have typically been difficult to diagnose, with definitive diagnoses taking years of testing. Previously, brain MRI scans were commonly used, but often provided non-specific results. With the advent of improved genetic testing methods, the Global Leukodystrophy Initiative (GLIA) Consortium has issued diagnostic guidelines that recommend use of a broad spectrum next-generation sequencing (NGS) panel, whole exome sequencing, or whole genome sequencing as the preferred first-line diagnostic tool. The new Transgenomic Leukodystrophy NGS Panel includes 137 genes and incorporates all of the genes GLIA recommends for testing. As the most comprehensive test on the market, it can potentially make definitive diagnoses accessible to patients and their families much earlier in the disease process.
“Leukodystrophy comprises a group of devastating genetic diseases that have been difficult to diagnose and almost impossible to treat,” said Paul Kinnon, President and Chief Executive Officer of Transgenomic. “We accordingly are very pleased to launch our Leukodystrophy NGS Panel, the most comprehensive genetic test for these conditions available today. By enabling clinicians to pinpoint the genetic source of the disorder earlier in the disease, we hope the Leukodystrophy NGS Panel will enable better disease management and facilitate the development of more effective therapies using new technologies, such as stem cells or gene editing techniques. This new test is another example of our commitment to harnessing advanced genetic tools to improve the lives of patients and families.”
The leukodystrophies are a group of about 40 inherited conditions in which the white matter of the brain is abnormal as a result of altered development or degeneration of the myelin sheath, the fatty covering that protects neurons. The condition results in progressive loss of neurologic function. Leukodystrophies often appear during infancy or early childhood, although the disease occasionally first manifests in adults. Diagnosis has typically been made by brain MRI, but many of the findings are non-specific. Most leukodystrophies result in progressive disability and death, often in childhood. Bone marrow transplantation is being performed for a few leukodystrophies, but current treatment is primarily supportive.
Robert Rauner, President of the United Leukodystrophy Foundation, commented, “On average it can take up to a decade to arrive at a definitive diagnosis for a leukodystrophy. Transgenomic’s genetic testing panel may help affected individuals arrive at a definitive diagnosis earlier to guide patient management decisions. This is very positive for those affected by leukodystrophy.”
Look how the short interest has exploded!
http://www.nasdaq.com/symbol/tbio/short-interest
My guess is you were wrong when you bought those puts, and tried to get everyone else to buy them.
As for the rest of it, I go back to what NWBO told RRRRIchmond:
You basically don't know what you are talking about.
GO NWBO!
I feel real confident that they will be approved.
Short Sales Are at Their Highest Level Since the Financial Crisis
Bloomberg By Lu Wang
http://finance.yahoo.com/news/short-sales-highest-level-since-134209395.html
We have been waiting for the FDA for months. This, I assume can come at any time. If you invest in biotech, you know how waiting for the FDA can be.
Tough day in the market for biotech:
SRNE down 7.24%
ZIOP down 6.58%
FPRX down 2.63%
KITE down 5.01%
MGNX down 4.04%
CELG down 2.83%
ATRA ** UP ** 5.42%
BMY down 0.72%
INCY down 3.04%
TSRO down 3.39%
NWBO down 1.08%
Maybe someone has margin call and need to sell whatever they can???
When we get the FDA approval, this will take off like a scalded cat!
Mya Thomae from Illumina
This is a key news release in my opinion. Why does anyone think the new board member is from Illumina?
http://finance.yahoo.com/news/transgenomic-expands-board-directors-executive-110000859.html
The 2nd appointment has experience with Life Technologies and Thermo Fisher.
Open to any thoughts......
Sure does seem like the shorts are still pounding away. We need the approval from the FDA. Then the shorts will be scurrying.
It is either end of quarter window undressing, or some shorts getting it ready to price an offering. It is unreal that this is capped at below $1.85.
List of possible customers for Cryoport who are developing cancer vaccines. The list is quite impressive.
http://www.reportlinker.com/p03041379-summary/Global-Cancer-Vaccines-Market.html
About Cancer Vaccines
Cancer vaccines are biological preparations that stimulate or strengthen a person’s immune system against cancer. Cancer vaccines are usually administered intravenously. They can be used in both adults and children. The vaccines can be broadly classified into two: prophylactic and therapeutic vaccines. Prophylactic vaccines are used for the prevention of cancer, whereas therapeutic vaccines are used for treatment of cancer.
Technavio's analysts forecast the global cancer vaccines market to grow at a CAGR of 27.24% over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the global cancer vaccines market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various therapeutic and prophylactic cancer vaccines.
This report covers the present scenario and the growth prospects of the global cancer vaccines market for the period 2015-2019 in the following three regions:
- Americas: The principal countries focused upon in this region are the US, Canada, Mexico, and Brazil
- EMEA: The principal countries focused upon in this region are the UK; Germany; Italy; France; Spain and Middle Eastern and African countries such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and UAE
- APAC: The principal countries focused upon in this region are Japan, China, Australia, Singapore, South Korea, and India. APAC is one of the major markets that is untapped by the leading vendors
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.
Technavio's report, Global Cancer Vaccines Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC; it also covers the global cancer vaccines market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
- Americas
- APAC
- EMEA
Key Vendors
- Dendreon
- GlaxoSmithKline
- Merck
Other Prominent Vendors
- Aduro BioTech
- Advantagene
- Advaxis
- Agenus
- AlphaVax
- Altor BioScience
- Amgen
- Antigen Express
- Argos Therapeutics
- AVAX Technologies
- Bavarian Nordic
- Biothera
- Bristol-Myers Squibb
- Celldex Therapeutics
- Cel-Sci
- CureVac
- Cytos
- Galena Biopharma
- Genexine
- GlobeImmune
- Gradalis
- Heat Biologics
- Immatics
- ImmunoCellular Therapeutics
- Immutep
- Inovio Pharmaceuticals
- Isa Pharmaceuticals
- Juvaris Biotherapeutics
- MedImmune
- NewLink Genetics
- Northwest Biotherapeutics
- NovaRx
- OncoThyreon
- Oncovir
- Oxford BioMedica
- Prima BioMed
- Progenics
- Provectus Biopharmaceuticals
- Sanofi
- Sotio
- Transgene
- Ubivac
- Vaccinogen
- Vaxon Biotech
- Vical
I am curious as to where you saw another 4 million was raised.
The last raise was for 6.2 million on March 4th.
Russell index adjustments could produce ____$40 bln trade flurry____
NEW YORK, May 29 (Reuters) - Investors trying to capitalize on the
annual tweaks to the makeup of Russell stock indexes may produce
a rush of transactions worth over $40 billion in the final moments
of trading on ___Friday, June 26, ___when those changes are formalized
The Wall Street summer ritual - often the biggest trading day of the
year - occurs when Russell Investments updates the component companies
in its Russell 1000, 2000 and 3000 indexes to keep up with the rise and
fall of U.S. corporations. Unlike index operators like Standard and
Poor's, which adds and removes components throughout the year, Russell
reconstitutes its indexes just once
On Friday, May 29, Russell will rank stocks based mostly on market
capitalization for eligibility in its indexes. Investors have been
attempting for months to predict which stocks could be affected.
TBIO added to Russell Microcap....
http://www.russell.com/indexes/americas/tools-resources/reconstitution/additions-deletions.page?#indexes